"All proceeds go to UCLA Johnson Cancer Center Foundation for the Research of Dr.
Noah Federman for Pediatric Sarcoma Cancers"
Dr. Noah Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center. Dr. Federman specializes in treating children, adolescents and young adults with these aggressive cancers. He runs a incredibly comprehensive and & multidisciplinary program involving pediatric and medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists. Dr. Federman also specializes in conducting clinical trials and leads an experienced clinical research team devoted to providing access to clinical trials for children with refractory, recurrent and metastatic bone and soft tissue cancers.
Pediatric Sarcomas, specifically Ewing sarcoma (ES), is a highly aggressive bone and soft tissue cancer that affects mainly children age 5 to 25. Only 3 in a million cases are reported each year, which makes it one of the rarest pediatric cancers. The pelvis is the most common area, followed by femur, tibia, humerus, and scapula. 5 year survival for a localized tumor is 70-70%, whereas it is 15%-20% when the tumor has spread at time of diagnosis. Higher dosages of the chemotherapy drugs in shorter intervals have improved the outcome over the past 30 years. It is critical to be treated at a hospital that is experienced with ES.
Hepatoblastoma Is a rare malignant liver cancer occurring primarily in infants and children under the age of three. Surgical removal of the tumor, adjuvant chemotherapy and liver transplantation have been used to treat hepatoblastoma. Primary liver transplantation provides, long term, disease free survival rate in the range of 80%. The presence of metastases is the strongest predictor of a poor prognosis. Hepatoblastoma is diagnosed in fewer than one million children.
A study is being done by Dr. Federman in order to find out if a new drug called TK216 helps in the treatment for Ewing Sarcoma. The purpose of the phase I part of this study is to test the safety of TK216 in the treatment of advanced cancer. The study will try to find the highest dose of TK216 that can be given without causing severe side effects. To date, C2C has raised over $130,000 for Dr. Federman’s Research Fund.